BioSpace News Archive

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Cipher Pharmaceuticals Inc. (TSX: CPH) today announced its financial and operating results for the three and twelve months ended December 31, 2020

Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share

Health Canada confirms that the benefits of the AstraZeneca COVID-19 vaccine in protecting Canadians from COVID-19 continue to outweigh the risks, and encourages Canadians to get immunized with any of the COVID-19 vaccines that are authorized in Canada.

After a temporary suspension of AstraZeneca vaccine across several EU countries due to concerns about rare adverse reactions, many nations plan to restart vaccinations following European Medicines Agency’s conclusion that the benefits of the vaccine far outweigh the risks.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

In a release issued earlier today under the same headline by Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), please note that in the last sentence of the first paragraph under the “Fourth Quarter 2020 Operational Highlights” section, the COVID-19 test is an antigen test, not an antibody test.

With students in nursing, physical therapy, occupational therapy and veterinary science, one thing was clear to Stanbridge University when the coronavirus started shutting down much of the world last spring: their students needed to be back on campus for essential lab and clinical learning, but only if it could be done safely.

Investments towards automation of supply management systems for forecasting demand with contingency plans will remain key to growth strategies in terms of sales.

This report analyzes the current and future scenario of the global brachytherapy devices market for the period 2018-2026.